Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 123-140

  Childs Disney, Jessica L ^a   Disney, Matthew D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibacterials; Antisense oligonucleotides; Genetic disease; Inforna; Nucleic acids; Orphan disease; Rational design; RNA; Target identification

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MICRORNA; OLIGONUCLEOTIDE; RNA; MOLECULAR LIBRARY;

ARTICLE; CELL FUNCTION; CHEMICAL CROSS LINKING AND ISOLATION BY PULL DOWN; CHEMICAL REACTIVITY AND BINDING ISOLATED BY PULL DOWN; DRUG DESIGN; DRUG TARGETING; HUMAN; MOLECULAR WEIGHT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROCEDURES; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA PULL DOWN; RNA SEQUENCE; ANIMAL; GENETIC DISEASES, INBORN; GENETICS; METABOLIC DISEASES; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; THERAPEUTIC USE;

ANIMALS; DRUG DESIGN; GENETIC DISEASES, INBORN; HUMANS; METABOLIC DISEASES; NEOPLASMS; RNA; SMALL MOLECULE LIBRARIES;

EID: 84954137639     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103910     Document Type: Article

References (95)

1. Batey RT, Rambo RP, Doudna JA. 1999. Tertiary motifs in RNA structure and folding. Angew. Chem. Int. Ed. Engl. 38:2326-43
2. Doudna JA. 2000. Structural genomics of RNA. Nat. Struct. Biol. 7(Suppl.):954-56
3. SicotG,Gomes-Pereira M. 2013. RNA toxicity in human disease and animal models: from the uncovering of a new mechanism to the development of promising therapies. Biochim. Biophys. Acta 1832:1390-409
4. Visone R, Croce CM. 2009. MiRNAs and cancer. Am. J. Pathol. 174:1131-38
5. Swayze EE, Bhat B. 2008. The medicinal chemistry of oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 143-82. Boca Raton, FL: CRC
6. Guan L, Disney MD. 2012. Recent advances in developing small molecules targeting RNA. ACS Chem. Biol. 7:73-86
7. Gallego J, Varani G. 2001. Targeting RNA with small-molecule drugs: Therapeutic promise and chemical challenges. Acc. Chem. Res. 34:836-43
8. Thomas JR, Hergenrother PJ. 2008. Targeting RNA with small molecules. Chem. Rev. 108:1171-224
9. Nesterova M, Cho-Chung YS. 2004. Killing the messenger: Antisense DNA and siRNA. Curr. Drug Targets 5:683-89
10. SierakowskaH, Agrawal S, Kole R. 2000. Antisense oligonucleotides as modulators of pre-mRNA splicing. Methods Mol. Biol. 133:223-33
11. Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. 2000. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407:340-48
12. Poehlsgaard J, Douthwaite S. 2005. The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 3:870-81
13. Yonath A, Bashan A. 2004. Ribosomal crystallography: Initiation, peptide bond formation, and amino acid polymerization are hampered by antibiotics. Annu. Rev. Microbiol. 58:233-51
14. Gareiss PC, Sobczak K, McNaughton BR, Palde PB, Thornton CA,Miller BL. 2008. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J. Am. Chem. Soc. 130:16254-61
15. Jahromi AH, Nguyen L, Fu Y, MillerKA, Baranger AM, Zimmerman SC. 2013. A novelCUGexpMBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1. ACS Chem. Biol. 8:1037-43
16. Childs-Disney JL, Hoskins J, Rzuczek SG, Thornton CA, Disney MD. 2012. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem. Biol. 7:856-62
17. Kumar A, Parkesh R, Sznajder LJ, Childs-Disney JL, Sobczak K, Disney MD. 2012. Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chem. Biol. 7:496-505
18. Tran T, Childs-Disney JL, Liu B, Guan L, Rzuczek S, DisneyMD. 2014. Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem. Biol. 9:904-12
19. Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, et al. 2014. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83:1043-50
20. Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, et al. 2009. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: Application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J. Am. Chem. Soc. 131:9767-79
21. Velagapudi SP, Disney MD. 2014. Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor. Chem. Commun. 50:3027-29
22. Velagapudi SP, Gallo SM, Disney MD. 2014. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat. Chem. Biol. 10:291-97
23. Bose D, Jayaraj G, Suryawanshi H, Agarwala P, Pore SK, et al. 2012. The tuberculosis drug streptomycin as a potential cancer therapeutic: inhibition of miR-21 function by directly targeting its precursor. Angew. Chem. Int. Ed. Engl. 51:1019-23
24. Guan L, Disney MD. 2013. Small molecule-mediated cleavage of RNA in living cells. Angew. Chem. Int. Ed. Engl. 52:1462-65
25. Guan L, Disney MD. 2013. Covalent small molecule-RNA complex formation enables cellular profiling of small molecule-RNA interactions. Angew. Chem. Int. Ed. Engl. 52:10010-13
26. Stephenson ML, Zamecnik PC. 1978. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. PNAS 75:285-88
27. Zamecnik PC, StephensonML. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. PNAS 75:280-84
28. KellerW, Crouch R. 1972. Degradation of DNA RNA hybrids by ribonucleaseH and DNA polymerases of cellular and viral origin. PNAS 69:3360-64
29. Agrawal S. 1999. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta 1489:53-68
30. Arechavala-Gomeza V, Khoo B, Aartsma-Rus A. 2014. Splicing modulation therapy in the treatment of genetic diseases. Appl. Clin. Genet. 7:245-52
31. Farooqi AA, Rehman ZU, Muntane J. 2014. Antisense therapeutics in oncology: current status. Onco Targets Ther. 7:2035-42
32. Lorenzer C, Dirin M, Winkler AM, Baumann V,Winkler J. 2015. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release 203:1-15
33. Lima WF, Monia BP, Ecker DJ, Freier SM. 1992. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31:12055-61
34. Monia BP, SasmorH, Johnston JF, Freier SM,LesnikEA, et al. 1996. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. PNAS 93:15481-84
35. Lacerra G, SierakowskaH,CarestiaC, Fucharoen S, Summerton J, et al. 2000. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. PNAS 97:9591-96
36. Suwanmanee T, Sierakowska H, Fucharoen S, Kole R. 2002. Repair of a splicing defect in erythroid cells from patients with thalassemia/HbE disorder. Mol. Ther. 6:718-26
37. Sazani P, Gemignani F, Kang SH,MaierMA, ManoharanM, et al. 2002. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20:1228-33
38. La Spada AR, Paulson HL, Fischbeck KH. 1994. Trinucleotide repeat expansion in neurological disease. Ann. Neurol. 36:814-22
39. Orr HT, Zoghbi HY. 2007. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30:575-621
40. Ranum LP, Cooper TA. 2006. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29:259-77
41. Liquori CL, Ricker K, MoseleyML, Jacobsen JF, Kress W, et al. 2001. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293:864-67
42. Mankodi A, Logigian E, Callahan L, McClain C, White R, et al. 2000. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289:1769-73
43. DeJesus-HernandezM,Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245-56
44. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257-68
45. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, et al. 1983. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306:234-38
46. Wheeler TM, Leger AJ, Pandey SK,MacLeod AR, Nakamori M, et al. 2012. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488:111-15
47. Mulders SA, van den BroekWJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, et al. 2009. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. PNAS 106:13915-20
48. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, et al. 2009. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325:336-39
49. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, et al. 2009. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 27:478-84
50. Gagnon KT, Watts JK, Pendergraff HM, Montaillier C, Thai D, et al. 2011. Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. J. Am. Chem. Soc. 133:8404-7
51. Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, et al. 2013. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126:829-44
52. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, et al. 2013. Unconventional translation of C9ORF72GGGGCCexpansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77:639-46
53. Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, et al. 2013. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80:415-28
54. Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, et al. 2013. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. PNAS 110:E4530-39
55. Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, et al. 2013. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 126:385-99
56. May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, et al. 2014. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 128:485-503
57. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, et al. 2013. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335-38
58. Turner DH, Sugimoto N, Freier SM. 1988. RNA structure prediction. Annu. Rev. Biophys. Biophys. Chem. 17:167-92
59. Deigan KE, Li TW, Mathews DH, Weeks KM. 2009. Accurate SHAPE-directed RNA structure determination. PNAS 106:97-102
60. Mathews DH, Disney MD, Childs JL, Schroeder SJ, Zuker M, Turner DH. 2004. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. PNAS 101:7287-92
61. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406-15
62. WoeseCR, Magrum LJ,GuptaR, SiegelRB, Stahl DA, et al. 1980. Secondary structure model for bacterial 16S ribosomal RNA: phylogenetic, enzymatic and chemical evidence. Nucleic Acids Res. 8:2275-93
63. Gutell RR, Weiser B, Woese CR, Noller HF. 1985. Comparative anatomy of 16-S-like ribosomal RNA. Prog. Nucleic Acid Res. Mol. Biol. 32:155-216
64. Childs-Disney JL,WuM, Pushechnikov A, Aminova O, Disney MD. 2007. A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem. Biol. 2:745-54
65. Disney MD, Labuda LP, Paul DJ, Poplawski SG, Pushechnikov A, et al. 2008. Two-dimensional combinatorial screening identifies specific aminoglycoside-RNA internal loop partners. J. Am. Chem. Soc. 130:11185-94
66. Auerbach T, Mermershtain I, Davidovich C, Bashan A, Belousoff M, et al. 2010. The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics. PNAS 107:1983-88
67. Borovinskaya MA, Pai RD, Zhang W, Schuwirth BS, Holton JM, et al. 2007. Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nat. Struct. Mol. Biol. 14:727-32
68. Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, et al. 2008. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51:3353-56
69. Moehle K, Athanassiou Z, Patora K, Davidson A, Varani G, Robinson JA. 2007. Design of hairpin peptidomimetics that inhibit binding of helical HIV-1 Rev protein to the Rev response element RNA. Angew. Chem. Int. Ed. Engl. 46:9101-4
70. Athanassiou Z, Patora K, Dias RL, Moehle K, Robinson JA, Varani G. 2007. Structure-guided peptidomimetic design leads to nanomolar hairpin inhibitors of the Tat-TAR interaction of bovine immunodeficiency virus. Biochemistry 46:741-51
71. Leeper TC, Athanassiou Z, Dias RL, Robinson JA, Varani G. 2005. TAR RNA recognition by a cyclic peptidomimetic of Tat protein. Biochemistry 44:12362-72
72. Davidson A, Patora-Komisarska K, Robinson JA, Varani G. 2011. Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein. Nucleic Acids Res. 39:248-56
73. LalondeMS, LobritzMA, Ratcliff A, Chamanian M, Athanassiou Z, et al. 2011. Inhibition of bothHIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLOS Pathog. 7:e1002038
74. Davidson A, Leeper TC, Athanassiou Z, Patora-Komisarska K, Karn J, et al. 2009. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. PNAS 106:11931-36
75. Stelzer AC, Kratz JD, Zhang Q, Al-Hashimi HM. 2010. RNA dynamics by design: biasing ensembles towards the ligand-bound state. Angew. Chem. Int. Ed. Engl. 49:5731-33
76. Stelzer AC, Frank AT, Kratz JD, Swanson MD, Gonzalez-Hernandez MJ, et al. 2011. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. Nat. Chem. Biol. 7:553-59
77. Lee MM, Pushechnikov A, Disney MD. 2009. Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem. Biol. 4:345-55
78. Childs-Disney JL, Yildirim I, Park H, Lohman JR, Guan L, et al. 2014. Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity. ACS Chem. Biol. 9:538-50
79. Rzuczek SG, Gao Y, Tang ZZ, Thornton CA, Kodadek T, Disney MD. 2013. Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem. Biol. 8:2312-21
80. AgnewHD, Rohde RD, Millward SW, Nag A, Yeo WS, et al. 2009. Iterative in situ click chemistry creates antibody-like protein-capture agents. Angew. Chem. Int. Ed. Engl. 48:4944-48
81. Kolb HC, Finn MG, Sharpless KB. 2001. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl. 40:2004-21
82. Lewis WG, Green LG, Grynszpan F, Radic Z, Carlier PR, et al. 2002. Click chemistry in situ: Acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Ed. Engl. 41:1053-57
83. Millward SW, Henning RK,Kwong GA, Pitram S, AgnewHD, et al. 2011. Iterative in situ click chemistry assembles a branched capture agent and allosteric inhibitor for Akt1. J. Am. Chem. Soc. 133:18280-88
84. Rzuczek SG, Park H, Disney MD. 2014. A toxicRNAcatalyzes the in cellulo synthesis of its own inhibitor. Angew. Chem. Int. Ed. Engl. 53:10956-59
85. Stern S, Moazed D, Noller HF. 1988. Structural analysis of RNA using chemical and enzymatic probing monitored by primer extension. Methods Enzymol. 164:481-89
86. MoazedD,NollerHF. 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327:389-94
87. Regulski EE, Breaker RR. 2008. In-line probing analysis of riboswitches. Methods Mol. Biol. 419:53-67
88. Lomenick B, Olsen RW, Huang J. 2011. Identification of direct protein targets of small molecules. ACS Chem. Biol. 6:34-46
89. Liang FS, Greenberg WA, Hammond JA, Hoffmann J, Head SR,Wong CH. 2006. Evaluation of RNAbinding specificity of aminoglycosides with DNA microarrays. PNAS 103:12311-16
90. Rijal K, Bao X, Chow CS. 2014. Amino acid-linked platinum(II) analogues have altered specificity for RNA compared to cisplatin. Chem. Commun. 50:3918-20
91. Rijal K, Chow CS. 2008. A new role for cisplatin: probing ribosomal RNA structure. Chem. Commun. 1:107-9
92. Hostetter AA, Osborn MF, DeRose VJ. 2012. RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. ACS Chem. Biol. 7:218-25
93. Moghaddam AD, White JD, Cunningham RM, Loes AN, Haley MM, DeRose VJ. 2015. Convenient detection of metal-DNA, metal-RNA, and metal-protein adducts with a click-modified Pt(II) complex. Dalton Trans. 44:3536-39
94. Osborn MF, White JD, Haley MM, DeRose VJ. 2014. Platinum-RNA modifications following drug treatment in S. cerevisiae identified by click chemistry and enzymatic mapping. ACS Chem. Biol. 9:2404-11
95. White JD, Osborn MF, Moghaddam AD, Guzman LE, Haley MM, DeRose VJ. 2013. Picazoplatin, an azide-containing platinum(II) derivative for target analysis by click chemistry. J. Am. Chem. Soc. 135:11680-83